目前，利用生物相容性药物材料开发功能性衍生物已成为迫切的需求。其中，抗坏血酸衍生物抗坏血酸-2-葡萄糖苷（AA-2G）由于其稳定性、增溶性和抗氧化前景而具有巨大的潜力。在此，AA-2G用于制造伊曲康唑（ITZ）spanlastics，其被称为“glucospanlastics”。随后，对新设计的葡聚糖进行了表征，以确定其尺寸、电荷、包埋、增溶效率、形态、稳定性和抗氧化活性。此外，还研究了它们对 A431 细胞的细胞毒性及其离体皮肤沉积。随后，在体内评估了含有葡糖醛酸的配制乳膏抑制艾利希癌和调节抗氧化特性的能力。结果表明，所提出的纳米级 glucospanlastics 在最佳溶解效率和 ITZ 截留（> 95%）以及抗氧化、细胞毒性和皮肤渗透潜力方面比传统的 glucospanlastics（不含 AA-2G）表现更好。更重要的是，含有 10 和 20 mg AA-2G 的葡糖醛酸显示出显着的肿瘤抑制和坏死作用，谷胱甘肽 (GSH) 含量提高 1.68 倍和 2.26 倍，总抗氧化能力 (TAC) 水平提高 1.67 倍和 2.84 倍与传统 ITZ 乳膏相比，丙二醛 (MDA) 水平分别降低 1.78 倍和 2.03 倍。这些创新的抗氧化囊泡显示了皮肤治疗癌症定向疗法的未来潜力。该期刊版权所有©英国皇家化学学会。

Presently, the development of functional derivatives exploiting biocompatible pharmaceutical materials has become a pressing demand. Among them, ascorbyl-2-glucoside (AA-2G), an ascorbic acid derivative, has significant potential owing to its stability, solubilization and antioxidant prospects. Herein, AA-2G was utilized for the fabrication of itraconazole (ITZ) spanlastics, which were denoted as "glucospanlastics". Subsequently, the newly designed glucospanlastics were characterized to determine their dimensions, charge, entrapment, solubilization efficiency, morphology, stability and antioxidant activity. Further, their cytotoxicity towards A431 cells and their ex vivo skin deposition were investigated. Subsequently, the competence of the formulated cream containing glucospanlastics to suppress Ehrlich carcinoma and modulate the antioxidant profile was evaluated in vivo. The results revealed that the proposed nano-sized glucospanlastics performed better than conventional spanlastics (without AA-2G) with respect to optimal solubilization efficiency and ITZ entrapment (>95%) together with antioxidant, cytotoxic and skin permeation potentials. More importantly, glucospanlastics containing 10 and 20 mg AA-2G demonstrated considerable tumor suppression and necrosis, improvement in glutathione (GSH) content by 1.68- and 2.26-fold, elevation of total antioxidant capacity (TAC) levels by 1.67- and 2.84-fold and 1.78- and 2.03-fold reduction in malondialdehyde (MDA) levels, respectively, compared to a conventional ITZ cream. These innovative antioxidant vesicles show future potential for the dermal delivery of cancer-directed therapies.This journal is © The Royal Society of Chemistry.